| 3/1/2010 |
 |
Fenwick & West Adds Prominent IP Litigation Partner in Seattle |
| |
|
| Fenwick & West LLP, a leading technology and life sciences law firm with offices in Seattle, Silicon Valley and San Francisco, is pleased to announce today that prominent Seattle-based patent litigation lawyer, David K. Tellekson, ... more |
|
|
| 1/21/2010 |
|
Fenwick & West Represents DexCom in $35M Follow-on Offering |
| |
|
| Fenwick & West LLP represented DexCom, Inc. (Nasdaq: DXCM), a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems, in its $35 million follow-on public offering... more |
|
|
| 1/12/2010 |
|
Fenwick & West Represents ZymoGenetics in $96.6 Million Follow-on Offering |
| |
|
| Fenwick & West LLP represented ZymoGenetics, Inc. (NASDAQ: ZGEN), a biopharmaceutical company focused on the development and commercialization of therapeutic proteins, in a $96.6 million follow-on public offering ... more |
|
|
| 12/9/2009 |
|
PTO Pilot Program To Speed Up Some Green-Tech Patent Applications |
| |
|
| Stuart Meyer, partner in the Intellectual Property Group at Fenwick & West LLP, was recently quoted in the National Law Journal article, "PTO Pilot Program To Speed Up Some Green-Tech Patent Applications."... more |
|
|
| 10/16/2009 |
|
Fenwick & West Files Ariad v. Eli Lilly Amicus Brief on Behalf of Eight Universities |
| |
|
| Fenwick & West LLP yesterday filed an amicus brief with the Federal Circuit on behalf of the country's leading research institutions, including The Regents of the University of California... more |
|
|
| 9/1/2009 |
|
Doctoring The Lilly Doctrine |
| |
|
| Michael Shuster, Ph.D., partner in the Intellectual Property Group and Co-Chair of the Life Sciences Group at Fenwick & West LLP, was recently quoted in the BioCentury article, "Doctoring The Lilly Doctrine."... more |
|
|
| 7/1/2009 |
|
Technology Transfer Considerations for Stem Cell Technologies |
| |
|
| Andrew T. Serafini, Ph.D., Partner in the Intellectual Property Group at Fenwick & West LLP, and Melissa Harwood, Patent Agent in the Intellectual Property Group at Fenwick & West LLP, were published in the ... more |
|
|
| 5/21/2009 |
|
Patents for Human Genes Face Legal Challenge |
| |
|
| Fenwick & West Partner Dr. Michael Shuster was quoted in a MedPage Today article titled "Patents for Human Genes Face Legal Challenge."... more |
|
|
| 4/8/2009 |
|
Michael Shuster Named One of California's Top IP Portfolio Managers |
| |
|
| Fenwick & West congratulates Michael Shuster, Intellectual Property Partner and Co-Chair of the firm's Life Sciences Group, for being named one of the Top 25 Leading Portfolio Managers ... more |
|
|
| 4/6/2009 |
|
Gilead’s Hypertension Drug Darusentan Will Likely Receive Patent Extension, Attorneys Say |
| |
|
| Narinder Banait was recently quoted in the Pharmawire article, "Gilead's Hypertension Drug Darusentan Will Likely Receive Patent Extension, Attorneys Say."... more |
|
|
| 3/2/2009 |
|
Fenwick & West's Silicon Valley Venture Capital Survey Reveals Valuations Weakening in Fourth Quarter of 2008 |
| |
|
| Fenwick & West LLP today announced results of its Fourth Quarter 2008 Silicon Valley Venture Capital Survey... more |
|
|
| 2/17/2009 |
|
M&A Activity Likely to Heat Up in Stem Cell Space Following Reversal on Federal Funding, Experts Say |
| |
|
| Narinder Banait, a partner in the Life Sciences Group with Fenwick & West, was recently quoted in the Pharmawire article, "M&A Activity Likely to Heat ... more |
|
|
| 2/11/2009 |
|
Fenwick & West Represents DexCom in $48M Public Offering |
| |
|
| Fenwick & West recently represented client DexCom, Inc. (Nasdaq: DXCM) in its $48 million offering of 15,844,000 shares of its common stock ... more |
|
|
| 12/11/2008 |
|
Fenwick & West Congratulates Monogram Biosciences on Biotech Patent Portfolio Ranking |
| |
|
| Fenwick & West congratulates its client Monogram Biosciences on placing 21st in the most recent Wall Street Journal Biotech Industry Patent Scorecard for biotech portfolios.... more |
|
|
| 11/10/2008 |
|
Green IP: A Thorny Challenge |
| |
|
| Fenwick & West partner Michael Shuster is quoted in the November 2008 ... more |
|
|
| 6/17/2008 |
|
Fenwick & West Represents LipoSonix in Acquisition by Medicis |
| |
|
| Fenwick & West LLP represented Bothell, WA-based LipoSonix, Inc. in its recently announced acquisition by Medicis (NYSE: MRX)... more |
|
|
| 5/28/2008 |
|
Fenwick & West Represents Becton in Acquisition of Cytopeia |
| |
|
| Fenwick & West LLP represented Becton, Dickinson and Company (NYSE: BDX) in its recently announced acquisition of Seattle, WA-based Cytopeia Inc.... more |
|
|
| 4/14/2008 |
|
Thriving Seattle Tech and Life Sciences Sector Draws National Law Firms to Washington |
| |
|
| Fenwick & West LLP was recently spotlighted in a National Law Journal article entitled, "Thriving Seattle Tech Sector Draws Law Firms." Stephen Graham, Managing Partner of the firm's Seattle ... more |
|
|
| 4/14/2008 |
|
Fenwick & West Continues to Grow its Seattle Office Rapidly; Adds IP Partner Andrew Serafini To Continue Expansion of Life Sciences Practice |
| |
|
| Fenwick & West LLP announced today the addition of Andrew T. Serafini, Ph.D., as a partner in its firmwide intellectual property group. ... more |
|
|
| 3/20/2008 |
|
Fenwick & West SF Bay Area Life Sciences Venture Capital Survey Reveals 45% Increase in Valuations |
| |
|
| Fenwick & West San Francisco Bay Area Life Sciences Venture Capital Survey Reveals 45% Increase in Valuations... more |
|
|
| 3/5/2008 |
|
Fenwick & West's San Francisco Bay Area Venture Capital Survey Shows Continued Improvement in Valuations in Fourth Quarter of 2007 |
| |
|
| Up Rounds Exceed Down Rounds for 16th Consecutive Quarter... more |
|
|
| 2/7/2008 |
|
Fenwick & West Adds Three Prominent Corporate Partners in Seattle;
Expands Life Sciences Practice |
| |
|
| Fenwick & West LLP announced today that three prominent Seattle corporate lawyers, Stephen M. Graham, Roger M. Tolbert and Alan C. Smith, have joined the firm and will launch its Seattle office.... more |
|
|
| 1/8/2008 |
|
Fenwick & West's San Francisco Bay Area Venture Capital Survey Reveals 79% Increase in Valuations in 3rd Quarter of 2007 |
| |
|
| Increase in Valuations is Largest Since Survey Began... more |
|
|
| 12/26/2007 |
|
Fenwick & West Elects Six New Partners |
| |
|
| Fenwick & West LLP announced that it has elected six associates to join the Firm's partnership, effective January 1, 2008... more |
|
|
| 9/10/2007 |
|
Digital Dialogue Revs Up at Top Firms |
| |
|
| Matt Kesner, Fenwick & West's Chief Technology Officer, was recently interviewed by Legal Technology News about the use of online collaboration, wireless tools and technical support teams at top law firms. ... more |
|
|
| 9/1/2007 |
|
VC Funding Trends for Life Science Firms |
| |
|
| Rob Dellenbach, a corporate partner at Fenwick & West, analyzes the number and value of venture capital investments in the healthcare, medical device and biopharmaceutical sectors... more |
|
|
| 3/28/2007 |
|
Fenwick & West's Third Annual San Francisco Bay Area Life Sciences Venture Capital Survey Reveals 50 |
| |
|
| Results Show a Continuation of the Positive Trend in the Life Science Venture Environment... more |
|
|
| 3/28/2007 |
|
Fenwick & West’s Third Annual San Francisco Bay Area Life Sciences Venture Capital Survey |
| |
|
| Results Show a Continuation of the Positive Trend in the Life Science Venture Environment... more |
|
|
| 10/23/2006 |
|
Fenwick & West Represents Connetics in $930 Million Merger with Stiefel Laboratories |
| |
|
| Fenwick & West LLP represented Connetics Corporation in its recently announced merger with Stiefel Laboratories, Inc., the world's largest independent pharmaceutical company specializing in dermatology.... more |
|
|
| 9/25/2006 |
|
Schwarz Jumps Into Pharma Consolidation Trend |
| |
|
| Sergio Garcia, co-chairman of Fenwick & West's Life Sciences Group was recently quoted in a Forbes article... more |
|
|
| 8/4/2006 |
|
Ariad v Lilly, Part II: The next big patent battle |
| |
|
| The pharmaceutical industry is paying close attention to an upcoming legal show down, slated for August 7, between Ariad Pharmaceuticals and Eli Lilly & Co. A U.S. District Court jury in May ... more |
|
|
| 7/23/2006 |
|
Pharmaceutical Giants View Biotech Players as Key to the Future |
| |
|
| Sergio Garcia, co-chairman of Fenwick & West’s Life Sciences Group was recently quoted in an Oakland Tribune article... more |
|
|
| 7/21/2006 |
|
Stem Cells: From DC to CA |
| |
|
| Michael J. Shuster, Ph.D., co-chair of the firm's Life Sciences Group was recently interviewed by Lisa Krieger, life science and biotech reporter with the San Jose Mercury News... more |
|
|
| 4/12/2006 |
|
Partnerships Drive Biotech Boom |
| |
|
| Sergio Garcia, co-chair of the Life Sciences practice group at Fenwick & West, was quoted in The Recorder’s front page article on the increase in partnership and collaboration deals ... more |
|
|
| 12/16/2005 |
|
Fenwick & West Represents Kleiner Perkins and Texas Pacific Group in Investment in Publicly-Traded Life Sciences Company |
| |
|
| Fenwick & West LLP represented investors Kleiner Perkins Caufield & Byers and Texas Pacific Group in their recently announced investment in BioCryst Pharmaceuticals (NASDAQ: BCRX)... more |
|
|
